Randomized Clinical Trial of Weekly vs. Triweekly Cisplatin-based chemotherapy Concurrent with Radiotherapy in the treatment of locally advanced Cervical Cancer
- Title
- Randomized Clinical Trial of Weekly vs. Triweekly Cisplatin-based chemotherapy Concurrent with Radiotherapy in the treatment of locally advanced Cervical Cancer
- Author
- 이원무
- Keywords
- Locally advanced cervical cancer; Tri-weekly cisplatin-based chemoradiation therapy
- Issue Date
- 2011-11
- Publisher
- Elsevier Science INC
- Citation
- International Journal of Radiation Oncology Biology and Physics, 2011, 81(4), P.E577-E581
- Abstract
- Purpose: To compare compliance, toxicity, and outcome of weekly and triweekly cisplatin administration concurrent with radiotherapy in locally advanced cervical cancer. Methods and Materials: In this open-label, randomized trial, 104 patients with histologically proven Stage IIB-IVA cervical cancer were randomly assigned by a computer-generated procedure to weekly (weekly cisplatin 40 mg/m(2), six cycles) and triweekly (cisplatin 75 mg/m(2) every 3 weeks, three cycles) chemotherapy arms during concurrent radiotherapy. The difference of compliance and the toxicity profiles between the two arms were investigated, and the overall survival rate was analyzed after 5 years. Results: All patients tolerated both treatments very well, with a high completion rate of scheduled chemotherapy cycles. There was no statistically significant difference in compliance between the two arms (86.3% in the weekly arm, 92.5% in the triweekly arm, p > 0.05). Grade 3-4 neutropenia was more frequent in the weekly arm (39.2%) than in the triweekly arm (22.6%) (p = 0.03). The overall 5-year survival rate was significantly higher in the triweekly arm (88.7%) than in the weekly arm (66.5%) (hazard ratio 0.375; 95% confidence interval 0.154-0.914; p = 0.03). Conclusions: Triweekly cisplatin 75-mg/m(2) chemotherapy concurrent with radiotherapy is more effective and feasible than the conventional weekly cisplatin 40-mg/m(2) regimen and may be a strong candidate for the optimal cisplatin dose and dosing schedule in the treatment of locally advanced cervical cancer.
- URI
- https://www.sciencedirect.com/science/article/pii/S0360301611006626?_rdoc=1&_fmt=high&_origin=gateway&_docanchor=&md5=b8429449ccfc9c30159a5f9aeaa92ffbhttps://repository.hanyang.ac.kr/handle/20.500.11754/72958
- ISSN
- 0360-3016
- DOI
- 10.1016/j.ijrobp.2011.05.002
- Appears in Collections:
- COLLEGE OF MEDICINE[S](의과대학) > MEDICINE(의학과) > Articles
- Files in This Item:
There are no files associated with this item.
- Export
- RIS (EndNote)
- XLS (Excel)
- XML